Stock Forecast

  Trevi Therapeutics, Inc. ( TRVI) Stock. Should you Buy or Sell?    $ 3.25

0.06 (1.81 %)

Trevi Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol TRVI
Price $3.25
Beta 0.209
Volume Avg. $1.54 M
Market Cap $139 M
52 Week Range $0.46 - $4.683

Trevi Therapeutics, Inc. opened the day at $3.25 which is +'1.81 % on yesterday's close. Trevi Therapeutics, Inc. has a 52 week high of $4.683 and 52 week low of $0.46, which is a difference of $4.223. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $139 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Trevi Therapeutics, Inc. for $139 M, it would take 15 years to get your money back. Trevi Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Trevi Therapeutics, Inc. Stock Forecast - Is Trevi Therapeutics, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -6.211
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Trevi Therapeutics, Inc.

Price Book Value Ratio 3.198 Price To Book Ratio 3.198
Price To Sales Ratio 0.000 Price Earnings Ratio -6.211

How liquid is Trevi Therapeutics, Inc.

Current Ratio 5.176
Quick Ratio 5.045


Debt Ratio 0.257 Debt Equity Ratio 0.345
Long Term Debt To Capitalization 0.082 Total Debt To Capitalization 0.171

Latest news about Trevi Therapeutics, Inc.

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

Date : 02/09/2022

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2022 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Serge Belanger – Needham & Company Leland Gershell – Oppenheimer Nathan Weinstein – Aegis Operator Good afternoon, and welcome to the Trevi Therapeutics Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Date : 14/08/2022

Trevi Therapeutics to Present at Upcoming August Conferences

NEW HAVEN, Conn. , Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences: Senior management at Trevi Therapeutics will be presenting at August investor and medical meeting conferences Stifel Biotech Executive Summer Summit (In-person) Date: Tuesday, August 16, 2022 Fireside chat presentation: Jennifer Good, President and CEO Time: 9:00 AM ET The fireside chat is an invitation-only event and will be available to attending participants.

Date : 09/08/2022

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn.

Date : 04/08/2022

How to Find Trending Penny Stocks in 2022

Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |

Date : 04/07/2022

About Trevi Therapeutics, Inc.

CEO : Ms. Jennifer Good
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Market

Description :

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

My Newsletter

Sign Up For Updates & Newsletters